Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP2 | O75604 | 3/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 4/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.43 |
| ▸ | MEN1 | O00255 | 3/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 3/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | F2 | P00734 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14788482 | 0.80 | LMNA (0.42) | USP2POLBALDH1A1L3MBTL1KMT2A | |
| SCHEMBL12639693 | 0.79 | USP2 (0.73) | USP2KDM4EPOLBALDH1A1L3MBTL1 | |
| SCHEMBL14788309 | 0.78 | USP2 (0.58) | USP2KDM4EPOLBALDH1A1L3MBTL1 | |
| SCHEMBL14788515 | 0.77 | USP2 (0.63) | USP2KDM4EPOLBALDH1A1L3MBTL1 | |
| SCHEMBL12639696 | 0.77 | USP2 (0.58) | USP2KDM4EPOLBALDH1A1L3MBTL1 | |
| SCHEMBL12696356 | 0.77 | USP2 (0.62) | USP2KDM4EPOLBALDH1A1L3MBTL1 | |
| SCHEMBL14788601 | 0.76 | USP2 (0.62) | USP2KDM4EPOLBALDH1A1L3MBTL1 | |
| SCHEMBL14788380 | 0.76 | USP2 (0.60) | USP2KDM4EPOLBALDH1A1L3MBTL1 | |
| SCHEMBL12639628 | 0.68 | MEN1 (0.59) | POLBALDH1A1KMT2AMEN1TSHR | |
| SCHEMBL14788566 | 0.64 | MEN1 (0.66) | ALDH1A1L3MBTL1KMT2AMEN1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130071328-A1 | Propynoic Acid Carbamoyl Methyl-Amides and Pharmaceutical Compositions and Methods Based Thereon | UNIVERSITY OF SOUTHERN CALIFORNIA (US) | 2013-03-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130071328-A1 | Propynoic Acid Carbamoyl Methyl-Amides and Pharmaceutical Compositions and Methods Based Thereon | RELA, NFE2, NCOA1 | USP2 1440/4885KDM4E 328/4885POLB 3598/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.